Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.

Details

Ressource 1Download: serval:BIB_B77FE9C209A9.P001 (82.76 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_B77FE9C209A9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Journal
Annals of Oncology
Author(s)
Maringwa J., Quinten C., King M., Ringash J., Osoba D., Coens C., Martinelli F., Reeve B.B., Gotay C., Greimel E., Flechtner H., Cleeland C.S., Schmucker-Von Koch J., Weis J., Van Den Bent M.J., Stupp R., Taphoorn M.J., Bottomley A., on behalf of the EORTC PROBE Project
Working group(s)
Brain Cancer Group
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2011
Volume
22
Number
9
Pages
2107-2112
Language
english
Notes
Publication types: JOURNAL ARTICLEPublication Status: ppublish
Abstract
BACKGROUND: We aimed to determine the smallest changes in health-related quality of life (HRQoL) scores in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 and the Brain Cancer Module (QLQ-BN20), which could be considered as clinically meaningful in brain cancer patients. Materials and methods: World Health Organisation performance status (PS) and mini-mental state examination (MMSE) were used as clinical anchors appropriate to related subscales to determine the minimal clinically important differences (MCIDs) in HRQoL change scores (range 0-100) in the QLQ-C30 and QLQ-BN20. A threshold of 0.2 standard deviation (SD) (small effect) was used to exclude anchor-based MCID estimates considered too small to inform interpretation. RESULTS: Based on PS, our findings support the following integer estimates of the MCID for improvement and deterioration, respectively: physical (6, 9), role (14, 12), and cognitive functioning (8, 8); global health status (7, 4*), fatigue (12, 9), and motor dysfunction (4*, 5). Anchoring with MMSE, cognitive functioning MCID estimates for improvement and deterioration were (11, 2*) and for communication deficit were (9, 7). Estimates with asterisks were <0.2 SD and were excluded from our MCID range of 5-14. CONCLUSION: These estimates can help clinicians evaluate changes in HRQoL over time, assess the value of a health care intervention and can be useful in determining sample sizes in designing future clinical trials.
Pubmed
Web of science
Open Access
Yes
Create date
23/09/2011 12:45
Last modification date
25/09/2019 6:10
Usage data